Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Conditions
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Castration-Resistant Prostate Carcinoma
- Clinical Stage III Gastric Cancer AJCC v8
- Clinical Stage IV Gastric Cancer AJCC v8
- HER2-Positive Breast Carcinoma
- Locally Advanced Breast Carcinoma
- Locally Advanced Gastric Carcinoma
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced Ovarian Carcinoma
- Locally Advanced Pancreatic Carcinoma
- Locally Advanced Prostate Carcinoma
- Metastatic Breast Carcinoma
- Metastatic Gastric Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Ovarian Carcinoma
- Metastatic Pancreatic Carcinoma
- Metastatic Prostate Carcinoma
- Platinum-Sensitive Ovarian Carcinoma
- Recurrent Breast Carcinoma
- Recurrent Gastric Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Pancreatic Carcinoma
- Recurrent Prostate Carcinoma
- Stage II Pancreatic Cancer AJCC v8
- Stage III Ovarian Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Stage IV Prostate Cancer AJCC v8
Interventions
- PROCEDURE: Biopsy Procedure
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Computed Tomography
- PROCEDURE: Magnetic Resonance Imaging
- DRUG: Talazoparib
Sponsor
National Cancer Institute (NCI)